Leerink Partners Boosts Insulet (NASDAQ:PODD) Price Target to $385.00

Insulet (NASDAQ:PODD) had its price target increased by investment analysts at Leerink Partners from $355.00 to $385.00 in a report issued on Friday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Leerink Partners’ price objective would suggest a potential upside of 18.34% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Raymond James Financial increased their target price on shares of Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research report on Friday. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Truist Financial raised their price target on shares of Insulet from $365.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Barclays upped their target price on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $367.74.

Insulet Price Performance

NASDAQ PODD traded up $1.93 on Friday, reaching $325.33. 68,467 shares of the stock traded hands, compared to its average volume of 718,270. Insulet has a 12 month low of $230.05 and a 12 month high of $353.50. The company has a market cap of $22.90 billion, a price-to-earnings ratio of 99.11, a P/E/G ratio of 2.64 and a beta of 1.39. The firm’s fifty day simple moving average is $325.46 and its 200 day simple moving average is $308.84. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter last year, the business posted $1.08 earnings per share. The company’s quarterly revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors have recently added to or reduced their stakes in PODD. Norges Bank bought a new position in shares of Insulet during the 2nd quarter worth approximately $324,689,000. Qube Research & Technologies Ltd bought a new stake in shares of Insulet in the second quarter worth $131,439,000. American Century Companies Inc. boosted its holdings in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Nuveen LLC acquired a new stake in Insulet in the 1st quarter valued at $74,163,000. Finally, Worldquant Millennium Advisors LLC bought a new stake in Insulet during the 2nd quarter worth about $80,082,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.